{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:17Z","timestamp":1777870337743,"version":"3.51.4"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-023-01701-0","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T05:02:06Z","timestamp":1688706126000},"page":"187-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proteinuria reduction with SGLT2 inhibitors in a patient treated with tyrosine kinase inhibitor lenvatinib"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-2732","authenticated-orcid":false,"given":"Victor","family":"Fages","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Maanaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Glowacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"1701_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/985780","volume":"2011","author":"ME Cabanillas","year":"2011","unstructured":"Cabanillas ME, Hu MI, Durand JB, Busaidy NL (2011) Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011:1\u20139","journal-title":"J Thyroid Res"},{"issue":"7","key":"1701_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621\u2013630","journal-title":"N Engl J Med"},{"issue":"12","key":"1701_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/ki.2011.288","volume":"80","author":"P Kandula","year":"2011","unstructured":"Kandula P, Agarwal R (2011) Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int 80(12):1271\u20131277","journal-title":"Kidney Int"},{"issue":"15","key":"1701_CR4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"11","key":"1701_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825","journal-title":"Ann Intern Med"},{"issue":"1","key":"1701_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1186\/s12885-021-08622-w","volume":"21","author":"C Masaki","year":"2021","unstructured":"Masaki C, Sugino K, Kobayashi S, Hosoi Y, Ono R, Yamazaki H et al (2021) Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients. BMC Cancer 21(1):894","journal-title":"BMC Cancer"},{"issue":"15","key":"1701_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98720","volume":"3","author":"P Cassis","year":"2018","unstructured":"Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C et al (2018) SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight 3(15):e98720","journal-title":"JCI Insight"},{"issue":"12","key":"1701_CR8","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.2215\/CJN.08900722","volume":"17","author":"P Vart","year":"2022","unstructured":"Vart P, Vaduganathan M, Jongs N, Remuzzi G, Wheeler DC, Hou FF et al (2022) Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes. CJASN 17(12):1754\u20131762","journal-title":"CJASN"},{"key":"1701_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2021.106949","volume":"142","author":"R Madonna","year":"2022","unstructured":"Madonna R, Barachini S, Moscato S, Ippolito C, Mattii L, Lenzi C et al (2022) Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: a potential rescue strategy. Vascul Pharmacol 142:106949","journal-title":"Vascul Pharmacol"},{"issue":"12","key":"1701_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.664181","volume":"29","author":"C Ren","year":"2021","unstructured":"Ren C, Sun K, Zhang Y, Hu Y, Hu B, Zhao J et al (2021) Sodium-glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK\u2013mTOR signaling pathway-mediated autophagy. Front Pharmacol 29(12):664181","journal-title":"Front Pharmacol"},{"issue":"4","key":"1701_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.5862","volume":"256","author":"M Locatelli","year":"2022","unstructured":"Locatelli M, Zoja C, Conti S, Cerullo D, Corna D, Rottoli D et al (2022) Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A\/caveolin-1\/PV-1 signaling pathway. J Pathol 256(4):468\u2013479","journal-title":"J Pathol"},{"issue":"1","key":"1701_CR12","doi-asserted-by":"publisher","first-page":"15695","DOI":"10.1038\/s41598-022-19988-7","volume":"12","author":"Y Tian","year":"2022","unstructured":"Tian Y, Chen X, Liang X, Wu X, Yao C (2022) SGLT2 inhibitors attenuate nephrin loss and enhance TGF-\u03b21 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial. Sci Rep 12(1):15695","journal-title":"Sci Rep"},{"issue":"7","key":"1701_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","volume":"8","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ et al (2020) Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol 8(7):582\u2013593","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1701_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","volume":"46","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Takahashi S (2019) Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol 46(1):57\u201364","journal-title":"Semin Oncol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01701-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01701-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01701-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:17Z","timestamp":1777564397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/1\/187\/8306217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["1701"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01701-0","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"29 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to disclose. On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was sought but not deemed necessary by the hospital research committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"There are no human and animal right issues to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The authors declare that they have obtained consent from the patient discussed in the report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}